Pre-Open Movers 04/30: (OSTK) (TSLA) (FB) Higher; (CHK) (HGV) (TWTR) Lower (more...)

April 30, 2020 9:27 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Today's Pre-Open Stock Movers:

Chesapeake Energy Corporation (NYSE: CHK) 41% LOWER; continues lower on potential bankruptcy filing

Orion Marine Group (NYSE: ORN) 26.6% HIGHER; reported Q1 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $166 million versus the consensus estimate of $157.97 million.

Matador Resources (NYSE: MTDR) 22.4% HIGHER; reported Q1 EPS of $0.20, $0.17 better than the analyst estimate of $0.03. Revenue for the quarter came in at $371.6 million versus the consensus estimate of $237 million.

Marker Therapeutics, Inc. (Nasdaq: MRKR) 22% HIGHER; announced that the United States Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug designation to MT-401, a multi-tumor-associated antigen (MultiTAA)-specific T cell product for the treatment of patients with acute myeloid leukemia (AML), following allogeneic stem cell transplant.

Overstock.com (NASDAQ: OSTK) 20% HIGHER; reported Q1 EPS of ($0.40), $0.23 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $352 million versus the consensus estimate of $332.3 million.

Ultra Clean Holdings (NASDAQ: UCTT) 14.4% HIGHER; reported Q1 EPS of $0.23, $0.21 worse than the analyst estimate of $0.44. Revenue for the quarter came in at $320.9 million versus the consensus estimate of $302.51 million.

MACOM Technology Solutions (NASDAQ: MTSI) 12.5% HIGHER; reported Q2 EPS of $0.17, $0.07 better than the analyst estimate of $0.10. Revenue for the quarter came in at $126.4 million versus the consensus estimate of $122.67 million. MACOM Technology Solutions sees Q3 2020 EPS of $0.19-$0.23, versus the consensus of $0.11. MACOM Technology Solutions sees Q3 2020 revenue of $129-133 million, versus the consensus of $123.2 million.

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) 10.8% HIGHER; announced that DSUVIA achieved Milestone C approval, a decision that clears the path for DSUVIA to be included in military sets, kits and outfits (SKOs).

Antero Resources (NYSE: AR) 10% HIGHER; reported Q1 EPS of ($0.13), $0.13 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $1.32 billion versus the consensus estimate of $945.27 million.

SIGA Technologies, Inc. (NASDAQ: SIGA) 9.5% HIGHER; announced the exercise of options under its 2018 Biomedical Advanced Research and Development Authority (BARDA) contract (“19C BARDA Contract”) worth a total of approximately $101.3 million for the procurement of oral TPOXX for the treatment of smallpox (tecovirimat). Deliveries of oral TPOXX to maintain national preparedness under these option exercises are expected to start in the second quarter of 2020 and be completed by April 2021. With the above-mentioned exercise of options, all procurement options under CLIN 9 (contract line item number 9) of the 19C BARDA Contract have been exercised. SIGA’s full 19C BARDA Contract has up to $414 million of procurement-related options remaining for future exercise.

Tesla (NASDAQ: TSLA) 7.3% HIGHER; reported Q1 EPS of $1.24, $1.60 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $5.99 billion versus the consensus estimate of $5.9 billion.

Hilton Grand Vacations (NYSE: HGV) 6.8% LOWER; reported Q1 EPS of $0.09, $0.39 worse than the analyst estimate of $0.48. Revenue for the quarter came in at $351 million versus the consensus estimate of $388.17 million.

Twitter (NYSE: TWTR) 6.7% LOWER; reported Q1 EPS of $0.11, $0.01 better than the analyst estimate of $0.10. Revenue for the quarter came in at $808 million versus the consensus estimate of $775.96 million.

Facebook (NASDAQ: FB) 6.1% HIGHER; reported Q1 EPS of $1.71, $0.03 worse than the analyst estimate of $1.74. Revenue for the quarter came in at $17.74 billion versus the consensus estimate of $17.48 billion. Facebook daily active users (DAUs) DAUs were 1.73 billion on average for March 2020, an increase of 11% year-over-year.

    Hartford Financial (NYSE: HIG) 5.2% LOWER; reported Q1 EPS of $1.34, $0.01 worse than the analyst estimate of $1.35. Revenue for the quarter came in at $4.96 billion versus the consensus estimate of $5.21 billion.

    Zoom (NASDAQ: ZM) 5.1% LOWER; Zoom video conferencing app does not have 300 million daily active users, the company admitted on Thursday to the Verge, saying it "unintentionally" referred to daily meeting participants as users in a blog post.

    Align Technology (NASDAQ: ALGN) 4.7% LOWER; reported Q1 EPS of $0.73, $0.27 worse than the analyst estimate of $1.00. Revenue for the quarter came in at $551 million versus the consensus estimate of $580.3 million.

    Inovalon (NASDAQ: INOV) 4.5% LOWER; reported Q1 EPS of $0.11, in-line with the analyst estimate of $0.11. Revenue for the quarter came in at $154.2 million versus the consensus estimate of $158.96 million. Inovalon sees FY2020 EPS of $0.53-$0.57, versus the consensus of $0.59. Inovalon sees FY2020 revenue of $672-698 million, versus the consensus of $701.4 million.

    ServiceNow (NYSE: NOW) 4.4% HIGHER; reported Q1 EPS of $1.05, $0.10 better than the analyst estimate of $0.95. Revenue for the quarter came in at $1.05 billion versus the consensus estimate of $1.02 billion.

    Microsoft (NASDAQ: MSFT) 3.1% HIGHER; reported Q3 EPS of $1.40, $0.14 better than the analyst estimate of $1.26. Revenue for the quarter came in at $35 billion versus the consensus estimate of $33.66 billion.

    Tapestry (NYSE: TPR) 2.8% LOWER; reported Q3 EPS of ($0.27), $0.16 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.03 billion.



    Serious News for Serious Traders! Try StreetInsider.com Premium Free!

    You May Also Be Interested In





    Related Categories

    Special Reports

    Related Entities

    Twitter, Tesla, Pre-Open Losers, Pre-Open Winners, Pre Market Movers, FDA